These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 34445283)
1. Small Molecule Receptor Binding Inhibitors with In Vivo Efficacy against Botulinum Neurotoxin Serotypes A and E. Ben David A; Barnea A; Diamant E; Dor E; Schwartz A; Torgeman A; Zichel R Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445283 [TBL] [Abstract][Full Text] [Related]
2. The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo. Ben David A; Diamant E; Barnea A; Rosen O; Torgeman A; Zichel R Clin Vaccine Immunol; 2013 Aug; 20(8):1266-73. PubMed ID: 23761665 [TBL] [Abstract][Full Text] [Related]
3. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. Dong M; Richards DA; Goodnough MC; Tepp WH; Johnson EA; Chapman ER J Cell Biol; 2003 Sep; 162(7):1293-303. PubMed ID: 14504267 [TBL] [Abstract][Full Text] [Related]
4. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain. Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503 [TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs. Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230 [TBL] [Abstract][Full Text] [Related]
6. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. Peng L; Tepp WH; Johnson EA; Dong M PLoS Pathog; 2011 Mar; 7(3):e1002008. PubMed ID: 21483489 [TBL] [Abstract][Full Text] [Related]
7. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. Rummel A; Häfner K; Mahrhold S; Darashchonak N; Holt M; Jahn R; Beermann S; Karnath T; Bigalke H; Binz T J Neurochem; 2009 Sep; 110(6):1942-54. PubMed ID: 19650874 [TBL] [Abstract][Full Text] [Related]
8. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin. Patel KB; Cai S; Adler M; Singh BK; Parmar VS; Singh BR Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30389764 [TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a novel botulinum neurotoxin. Zhang S; Masuyer G; Zhang J; Shen Y; Lundin D; Henriksson L; Miyashita SI; Martínez-Carranza M; Dong M; Stenmark P Nat Commun; 2017 Aug; 8():14130. PubMed ID: 28770820 [TBL] [Abstract][Full Text] [Related]
10. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain. Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA mSphere; 2016; 1(1):. PubMed ID: 27303710 [TBL] [Abstract][Full Text] [Related]
11. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Dong M; Liu H; Tepp WH; Johnson EA; Janz R; Chapman ER Mol Biol Cell; 2008 Dec; 19(12):5226-37. PubMed ID: 18815274 [TBL] [Abstract][Full Text] [Related]
12. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. Rummel A; Karnath T; Henke T; Bigalke H; Binz T J Biol Chem; 2004 Jul; 279(29):30865-70. PubMed ID: 15123599 [TBL] [Abstract][Full Text] [Related]
13. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin. Weisemann J; Stern D; Mahrhold S; Dorner BG; Rummel A Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196927 [TBL] [Abstract][Full Text] [Related]
14. Comparison of oral toxicological properties of botulinum neurotoxin serotypes A and B. Cheng LW; Henderson TD Toxicon; 2011 Jul; 58(1):62-7. PubMed ID: 21600236 [TBL] [Abstract][Full Text] [Related]
15. SV2 is the protein receptor for botulinum neurotoxin A. Dong M; Yeh F; Tepp WH; Dean C; Johnson EA; Janz R; Chapman ER Science; 2006 Apr; 312(5773):592-6. PubMed ID: 16543415 [TBL] [Abstract][Full Text] [Related]
16. In vitro potency determination of botulinum neurotoxin serotype A based on its receptor-binding and proteolytic characteristics. Behrensdorf-Nicol HA; Wild E; Bonifas U; Klimek J; Hanschmann KM; Krämer B; Kegel B Toxicol In Vitro; 2018 Dec; 53():80-88. PubMed ID: 30016653 [TBL] [Abstract][Full Text] [Related]
18. Uptake of botulinum neurotoxin into cultured neurons. Keller JE; Cai F; Neale EA Biochemistry; 2004 Jan; 43(2):526-32. PubMed ID: 14717608 [TBL] [Abstract][Full Text] [Related]
19. Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes. Baldwin MR; Barbieri JT Biochemistry; 2007 Mar; 46(11):3200-10. PubMed ID: 17311420 [TBL] [Abstract][Full Text] [Related]
20. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Mahrhold S; Strotmeier J; Garcia-Rodriguez C; Lou J; Marks JD; Rummel A; Binz T Biochem J; 2013 Jul; 453(1):37-47. PubMed ID: 23621114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]